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OBJECTIVES This study evaluated the effects of azimilide dihydrochloride (AZ) on anti-tachycardia pacing
(ATP) and shock-terminated events in patients with implantable cardioverter defibrillators
(ICDs).
BACKGROUND Animal studies have shown the effectiveness of AZ for therapy of supraventricular and
ventricular tachycardia (VT). Azimilide dihydrochloride was investigated as adjunctive
treatment for reducing the frequency of VT and, thus, the need for ICD therapies, including
ATP and cardioversion/defibrillation (ICD shocks) in patients with inducible monomorphic
VT.
METHODS A total of 172 patients were randomized to daily treatment with placebo, 35 mg, 75 mg, or
125 mg of oral AZ in this dose-ranging pilot study of patients with ICDs. The majority of
patients had a history of documented remote myocardial infarction and congestive heart
failure New York Heart Association class II or III.
RESULTS The frequency of appropriate shocks and ATP were significantly decreased among AZ-
treated patients compared with placebo patients. The incidence of ICD therapies per
patient-year among the placebo group was 36, and it was 10, 12, and 9 among 35 mg, 75 mg,
and 125 mg AZ patients, respectively (hazard ratio  0.31, p  0.0001). Azimilide
dihydrochloride was generally well tolerated and did not affect left ventricular ejection fraction
or minimal energy requirements for defibrillation or pacing.
CONCLUSIONS Azimilide dihydrochloride may be a safe and effective drug for reducing the frequency of VT
and ventricular fibrillation in patients with implanted ICDs. (J Am Coll Cardiol 2004;43:
39–43) © 2004 by the American College of Cardiology Foundation
Azimilide dihydrochloride (AZ) is a novel antiarrhythmic
that blocks rapid (IKr) and slow (IKs) (1) components of the
delayed rectifier cardiac potassium channels. The mecha-
nisms of action of AZ result in a rate independent class III
(Vaughan-Williams) effect in humans (2–4) and decreased
minimum energy requirements for defibrillation in animal
See page 44
studies (5). Azimilide dihydrochloride was effective and
generally well tolerated in patients with supraventricular
arrhythmia (6). The implantable cardioverter defibrillator
(ICD) is the treatment of choice for patients with life-
threatening ventricular tachyarrhythmias, and antiarrhyth-
mics have become increasingly more important as adjunctive
therapy for these patients. In fact, concomitant administra-
tion of antiarrhythmic drugs may be as high as 70% in
patients with ICDs (7). The use of antiarrhythmic drugs
with ICDs reduces the frequency of atrial fibrillation,
reduces sustained and non-sustained ventricular tachycardia
(VT), and improves the control of maximal sinus rate (8).
These beneficial effects of antiarrhythmics are achieved
more frequently by slowing VT rates and allowing termi-
nation by anti-tachycardia pacing (ATP) rather than by
preventing fast VT-triggered shocks (7). Therefore, the
efficacy of a concomitant antiarrhythmic therapy for patients
with ICDs should be evaluated by its ability to affect
frequencies of shocks and ATP (9). In this study we
investigated the effects of AZ on ATP and shock-
terminated events in patients with ICDs.
METHODS
A double-blind, placebo-controlled, pilot study of 172
patients with ICDs, recruited from 37 centers in the U.S.,
was initiated to determine the effect of AZ on the recur-
rence of ICD therapies (shocks and ATP) in patients with
documented VT at electrophysiologic study. Patients were
randomly assigned to receive either 35 mg, 75 mg, or 125
mg of oral AZ or placebo with stratification according to left
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ventricular ejection fraction (LVEF). Institutional review
board approval and written informed consent were obtained
before starting the study.
Patients were included in this study if they met one of the
following criteria: 1) an ICD implantation had occurred 30
days or more before randomization, and the patient had at
least one ICD shock within the preceding year; or 2) an
ICD had been implanted for symptomatic VT within 30
days of randomization, and the patient had an inducible
sustained monomorphic VT. In this case, patients were
required to have documented monomorphic VT or ventric-
ular fibrillation (VF) and to have an inducible VT or VF
upon non-invasive, programmed stimulation with an im-
planted ICD. A baseline electrophysiologic study was re-
quired, with induction and termination of VT with up to
three extrastimuli at cycle lengths of 600 and 400 ms.
Patients were excluded if they: 1) were 18 years of age;
2) had class IV, New York Heart Association heart failure;
3) were taking class I or class III antiarrhythmic agents; 4)
had unresolved angina pectoris or had experienced a myo-
cardial infarction within 90 days of randomization; 5) had
QTc longer than 440 ms or JTc 320 ms (if QRS 120
ms); 6) had a history of polymorphic VT, including Torsade
de Pointes (TdP); 7) had hypertrophic cardiomyopathy or
restrictive heart disease; 8) were hemodynamically unstable;
or 9) had clinically significant liver or renal dysfunction.
Patients were randomly assigned to receive 35 mg, 75 mg,
or 125 mg of oral AZ or placebo. All patients were evaluated
at week 2 and months 1, 3, 6, 9, and 12 after the
administration of AZ or placebo during which the following
safety assessments were made: 1) 12-lead electrocardiogram
(ECG); 2) physical examination with adverse event (AE)
assessment; and 3) clinical laboratory parameter assess-
ments. A 24-h ECG recording was obtained at baseline and
at the month-1 visit. A two-dimensional echocardiographic
assessment of LVEF was obtained at baseline and at the
month-6 visit. Non-invasive electrophysiologic testing to
determine minimal energy requirement for defibrillation
was performed at baseline and at the month-1 visit. The
ICD was interrogated at every visit, and stored electrograms
(EGMs) were retrieved. All patients were evaluated after a
documented ICD shock.
Appropriate ICD shock or ATP was defined as any ICD
therapy that occurred in response to a VT or VF retrieved
on stored EGMs. An events committee, composed of four
electrophysiologists, reviewed the blinded EGM data and
classified all arrhythmic events requiring ICD therapies.
Events were classified by an agreement of two reviewing
electrophysiologists. If there was a disagreement between
the two electrophysiologists, the tie was broken by a third
electrophysiologist. If no agreement could be reached, the
entire committee reviewed the disputed event until a con-
sensus could be achieved. If a consensus was not possible,
the majority opinion prevailed as the final interpretation.
Statistical methods. The Andersen-Gill proportional haz-
ards model (10) was used to analyze recurrent ICD thera-
pies. This model used all the ICD therapies that the
patients experienced during the follow-up period. In this
analysis, only tachycardia detections requiring appropriate
shock or ATP therapy were used. The Andersen-Gill
analysis was performed using SAS statistical software, Proc
Phreg, version 8.2 (SAS Institute, Cary, North Carolina).
In addition, an approximation of the log-rank test (11)
was used to compare the ICD therapy rate (incidence) per
patient-year exposure across treatment groups. This test is a
form of a simple chi-square test. It is used to compare VT
incidence between the groups. The test uses the reciprocal
of the total VT events for each treatment group as a
function of the variance of the test. This type of statistical
analysis is particularly useful in this instance because mul-
tiple VT events are experienced by some patients.
All appropriate ICD therapies were analyzed. Arrhyth-
mia episodes requiring multiple therapy deliveries to termi-
nate were considered a single event detection. Patients who
withdrew before completion of 374 days of the study
follow-up had their efficacy measure censored on the day of
the withdrawal.
RESULTS
Overall, 172 patients were randomized in this study, with 37
patients receiving placebo, 44 patients receiving 35 mg AZ,
45 patients receiving 75 mg AZ, and 46 patients receiving
125 mg AZ. Data from all 172 patients were included in the
statistical analysis. Most of the patients were followed up for
374 days with the mean (SD) follow-up of 279  143,
259  156, 285  136, and 247  158 days for placebo, 35
mg, 75 mg, and 125 mg, respectively. A total of 2,011
appropriate ICD therapies were detected in this study, with
a mean number of therapies per patient of 18  50 and a
median of 4. A total of 358 appropriate ICD shocks were
detected, with a mean number of shocks per patient of 4 
5 and a median of 2. Demographic and baseline cardiac
characteristics are presented in Table 1.
The majority of patients had an LVEF35% (62%) with
no significant differences among the treatment groups. The
Abbreviations and Acronyms
AE  adverse event
ATP  anti-tachycardia pacing
AZ  azimilide dihydrochloride
EGM  electrogram
HR  hazard ratio
ICD  implantable cardioverter defibrillator
IKr  rapid component of cardiac potassium channels
IKs  slow component of cardiac potassium channels
LVEF  left ventricular ejection fraction
PVC  premature ventricular contraction
TdP  Torsade de Pointes
VF  ventricular fibrillation
VT  ventricular tachycardia
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percentage of patients who withdrew from the study volun-
tarily was equally distributed among the treatment groups.
No differences were observed in blood pressure, heart rate,
or ECG variables. The use of concomitant medication was
similar among the groups.
AEs. The overall proportion of patients who reported AEs
was similar across all groups and is presented in Table 2.
Forty patients were withdrawn from the study because of
AEs, seven (19%) from placebo, and 33 (24%) from AZ
groups, overall. No differences were detected between the
placebo and AZ patients in the number of AEs that the
investigators considered drug related. The majority of the
reported serious AEs were cardiovascular. There were three
reported episodes of TdP in two patients (1 male and 1
female). Both patients were receiving 125 mg of AZ. In one
patient, TdP occurred after a short duration of exposure to
AZ, and in both patients it occurred within the context of
ongoing myocardial ischemia.
Effects of AZ on frequency of VT and VF. Azimilide
dihydrochloride significantly reduced the frequency of ap-
propriate ICD therapies (shocks and ATP-triggered by
VT/VF) at all administered doses by 69%, compared with
placebo (hazard ratio [HR]  0.31, p  0.0001, Table 3),
without affecting pacing or defibrillation or pacing thresh-
olds (Table 4). In addition, AZ significantly reduced the
frequency of VTs and the requirement for ATP therapies
by 66% to 79% (HR range  0.21 to 0.34, p  0.0001,
Table 3).
A dose-dependent reduction of VT frequency is paral-
leled by a similar trend in reduced frequency of premature
Table 1. Demographic and Baseline Cardiac Characteristics
Characteristics
Placebo
(n  37)
Azimilide Dihydrochloride
35 mg
(n  44)
75 mg
(n  45)
125 mg
(n  46)
Male 31 (84%) 41 (93%) 41 (91%) 41 (89%)
Age (yrs)* 65 (11) 69 (9) 64 (10) 65 (13)
LVEF (%)* 34 (14) 31 (11) 28 (12) 30 (14)
LVEF 35% 19 (51%) 26 (59%) 32 (71%) 29 (63%)
Heart rate (beats/min)* 74 (15) 70 (16) 70 (13) 73 (15)
QRS interval (ms)* 132 (34) 130 (32) 133 (29) 131 (31)
QTc value (ms)* 419 (20) 416 (21) 416 (15) 420 (28)
JTc value (ms)* 296 (23) 288 (31) 304 (35) 294 (19)
Previous MI 30 (81%) 34 (77%) 37 (82%) 38 (83%)
Diabetes 10 (27%) 6 (14%) 10 (22%) 13 (28%)
No CHF 9 (24%) 12 (27%) 10 (22%) 14 (30%)
NYHA class
I 15 (41%) 15 (34%) 16 (36%) 9 (20%)
II 12 (32%) 15 (34%) 13 (29%) 19 (41%)
III 1 (3%) 2 (5%) 6 (13%) 4 (9%)
Concomitant medications
during the study
Beta-blockers 16 (43%) 14 (32%) 22 (49%) 20 (44%)
ACE inhibitors 29 (78%) 35 (80%) 40 (89%) 32 (70%)
Diuretics 30 (81%) 32 (73%) 31 (69%) 33 (72%)
Calcium channel blockers 11 (30%) 12 (27%) 13 (29%) 12 (26%)
*Data shown are mean and SD.
ACE  angiotensin-converting enzyme; CHF  congestive heart failure; LVEF  left ventricular ejection fraction; MI 
myocardial infarction; n  number of patients; NYHA  New York Heart Association.
Table 2. Adverse Events for All Randomized Patients
Placebo 35 mg AZ 75 mg AZ 125 mg AZ
Number of patients randomized 37 44 45 46
Mean number of AEs per patient 5.9 4.5 6.2 6.0
Number (%) of patients with SAEs 17 (46%) 23 (52%) 20 (40%) 19 (41%)
Number of deaths 3 (8%) 1 (2%) 1 (2%) 0 (0%)
Number of patients with TdP 0 (0%) 0 (0%) 0 (0%) 2 (4%)
Number of patients with new or exacerbation of
VT reported as AE
9 (24%) 6 (14%) 8 (18%) 5 (11%)
Number of patients withdrawn for any reason 13 (35%) 18 (41%) 18 (40%) 22 (48%)
Number of patients withdrawn due to AEs 7 (19%) 10 (23%) 9 (20%) 14 (30%)
Number of patients with “drug-related” AEs 14 (38%) 14 (32%) 16 (36%) 17 (37%)
Number of patients hospitalized 16 (43%) 23 (52%) 20 (44%) 19 (41%)
*All the comparisons between placebo and AZ patients were not statistically significant (p  0.05).
AE  adverse event; ATP  anti-tachycardia pacing; AZ  azimilide; SAE  serious adverse event; TdP  Torsade de
Pointes; VT  ventricular tachycardia.
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ventricular contractions (PVCs) (Table 4). Of particular
importance is the observation that there was no significant
impact on LVEF, resting heart rate, or systemic pressure,
suggesting that AZ does not adversely affect cardiac func-
tion or hemodynamic variables in a very sick population of
patients (i.e., patients with impaired left ventricular func-
tion). A modest dose-dependent increase in QTc/JTc in-
tervals was noted, consistent with the anticipated action of
an IKr and IKs channel-blocking antiarrhythmic drug.
DISCUSSION
This dose-ranging study was conducted to test the effect of
AZ on the frequency of recurrent VT and VF. Recurrent
ICD therapies are documented and stored by the ICDs and
can therefore be easily retrieved, diagnosed, and validated as
a measure of antiarrhythmic drug efficacy in this patient
population. Because all patients are protected from sudden
cardiac death by the implanted ICDs, the relative reduction
in frequency of documented ICD therapies is an effective
surrogate measure of the antiarrhythmic drug efficacy for
VT and VF suppression.
Azimilide dihydrochloride caused a significant reduction
in the delivery of all appropriate programmed ICD thera-
pies. Previous studies with antiarrhythmic drugs in patients
with ICDs have reported the reduction of VT terminated by
ICD shocks (12,13). In the present study, we observed a
similar decrease in the occurrence of all appropriate ICD
therapies, both shocks and ATP triggered by VT/VF. A
dose-related decrease in PVC frequency in the 24-h ECG
data collected 30 days after dose initiation was also ob-
served. However, a clear dose response was not observed
regarding frequency of shocks and ATP. A lack of clear
separation is probably related to a relatively small sample
size among study groups.
Decreasing the recurrence of ICD therapies triggered by
VT/VF is clearly beneficial in the light of the well-
documented discomfort of ICD shocks, the worsening of
heart failure secondary to frequent VTs and resultant
therapies (ATP and shocks), and the negative psychological
impact of recurrent shocks, as well as other quality of life
issues (14–18). On a practical level, reducing the number of
inappropriate ICD therapies would also be expected to
enhance ICD longevity by conserving the battery drain (19).
Azimilide dihydrochloride was generally well tolerated.
No statistical differences were observed between placebo
and AZ patients among safety parameters reported in Table
2. Mortality was low and unrelated to tachyarrhythmic
events or drug-related AEs. Three episodes of TdP in two
Table 3. ICD Therapy Analysis
ITT Analysis: All Appropriate ICD Therapies (Shocks and ATP)
Treatment n
Hazard Ratio
(95% CI)
p Value
(AG Model)
Incidence per Pt-Year
(95% CI)
p Value
(Log-Rank)
Placebo 37 36 (34, 38.4)
35 mg AZ 44 0.31 (0.28, 0.36) 0.0001 10 (8.9, 11.1) 0.0001
75 mg AZ 45 0.31 (0.27, 0.34) 0.0001 12 (10.8, 13) 0.0001
125 mg AZ 46 0.31 (0.27, 0.36) 0.0001 9 (7.8, 9.8) 0.0001
Analysis of Frequency of Appropriate ATP Therapies
Treatment n
Hazard Ratio
(95% CI)
p Value
(AG Model)
Incidence per Pt-Year
(95% CI)
p Value
(Log-Rank)
Placebo 29 42.1 (39.4, 44.8)
35 mg AZ 35 0.26 (0.23, 0.31) 0.0001 9.1 (7.9, 10.3) 0.0001
75 mg AZ 31 0.34 (0.30, 0.39) 0.0001 13.8 (12.3, 15.3) 0.0001
125 mg AZ 36 0.21 (0.18, 0.25) 0.0001 6.8 (5.7, 7.9) 0.0001
AZ  azimilide; AG  Andersen-Gill model of proportional hazards for frequency of appropriate ATPs in patients with ATP therapy programmed “on” at any time during
the study; ATP  antitachycardia pacing; CI  confidence interval; ICD  implantable cardioverter defibrillator; Pt  patient.
Table 4. Median Percent Change From Baseline* (p Value)†
Placebo
(n  37)
35 mg
(n  44)
75 mg
(n  45)
125 mg
(n  46)
Heart rate (beats/min) 1.0 2.8 (0.95) 4.2 (0.68) 3.9 (0.82)
QTC/JTC (ms) 3.0 0.98 (0.27) 2.5 (0.31) 8.7 (0.02)
(PVC/24 h) 28% 24% (0.04) 38% (0.02) 66% (0.003)
Systolic BP 2.1 0.0 (0.30) 1.5 (0.45) 3.0 (0.03)
Diastolic BP 1.2 1.2 (0.95) 2.9 (0.61) 6.7 (0.16)
LVEF (%)‡ 1.5 1.9 (0.72) 7.4 (0.26) 5.9 (0.31)
mDFE (J)‡ 1.2 1.0 (0.06) 0.1 (0.32) 0.8 (0.92)
mPE (V)‡ 0.6 0.5 (0.11) 0.3 (0.10) 0.4 (0.60)
*Change from baseline to month 1 visit; †Wilcoxon rank-sum test; ‡Represents mean % change from baseline.
BP  blood pressure; LVEF  left ventricular ejection fraction; mDFE  minimal defibrillation energy; mPE  minimal
pacing energy; PVC  premature ventricular contractions percent.
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patients were effectively treated by the ICD without adverse
consequences. In both patients ischemia appeared to be the
immediate trigger.
Hemodynamic status was not affected by AZ treatment,
and results observed in this study (Table 3) were consistent
with results from previous studies with similar doses con-
ducted in patients with supraventricular tachyarrhythmias
(20).
Clinical implications. Significant decrease in the ICD
therapies (shocks and ATP), associated with a generally
favorable AE profile, suggests that AZ may have an impor-
tant role to play as adjunctive therapy for patients with
ICDs in the reduction of VT/VF that leads to recurrent
ICD therapies. A larger study called Shock Inhibition
Evaluation with AzimiLiDe (SHIELD) is underway to
confirm the findings of this pilot study.
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APPENDIX
For a complete list of clinical investigators who provided
and cared for study patients, please see the January 7, 2004,
issue of JACC at www.cardiosource.com/jacc.html.
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